Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy

@article{Saleeb2018ModulatingAB,
  title={Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy},
  author={Rola M. Saleeb and Mina S Farag and Zsuzsanna Lichner and Fadi Brimo and Jenni Bartlett and Georg A. Bjarnason and Antonio Finelli and Fabio Rontondo and Michelle R Downes and George M. Yousef},
  journal={Molecular Oncology},
  year={2018},
  volume={12},
  pages={1673 - 1688}
}
Papillary renal cell carcinoma (PRCC) is the most common nonclear cell RCCs and is known to comprise two histological subtypes. PRCC2 is more aggressive and is molecularly distinct from the other subtypes. Despite this, PRCCs are treated together as one entity, and they show poor response to the current therapies that do not target pathways implicated in their pathogenesis. We have previously detected ABCC2 (an ABC transporter), VEGF, and mTOR pathways to be enriched in PRCC2. In this study, we… 
Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities
TLDR
The authors summarize the current understanding of the mechanisms of resistance to currently used therapies in pRCC and make recommendations for future preclinical and clinical studies.
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
TLDR
An overview ofcell death-related molecules and biomarkers for the progression, prognosis and treatment of mRCC by targeted therapy, with a focus on apoptosis and T cell-induced cell death, as well as other forms of cell death.
Diagnostic and prognostic value of ABC transporter family member ABCG1 gene in clear cell renal cell carcinoma
TLDR
It is demonstrated that ABCG1 is a potential diagnostic and prognostic biomarker in ccRCC and the molecular mechanisms underlying the relationship between ccR CC andABCG1 are discussed, which might provide guidance for better management and treatment ofccRCC in the future.
Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8
TLDR
It is revealed that Lefty A can regulate sunitinib sensitivity of RCC cells of via NF-κB/IL-8 signals, indicating that targeted inhibition of Lefty might be a potent approach to overcome sunit inib resistance of R CC.
Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes
TLDR
Experimental studies on lipid membranes are necessary to identify drugs that may disturb membranes and characterize drug–membrane interactions on a molecular level to understand the efficacy and potential side effects of respective drugs.
Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer.
TLDR
The types of renal cancer are described and the studies that analyzed the role of organic cation transporters of the SLC22-family and of the aquaporin water channel family in kidney tumors are reviewed.

References

SHOWING 1-10 OF 64 REFERENCES
Papillary renal cell carcinoma: A review of the current therapeutic landscape.
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials.
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
TLDR
An overview ofcell death-related molecules and biomarkers for the progression, prognosis and treatment of mRCC by targeted therapy, with a focus on apoptosis and T cell-induced cell death, as well as other forms of cell death.
ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux
TLDR
ABCC transporters can affect neuroblastoma biology independently of their role in chemotherapeutic drug efflux, enhancing their potential as targets for therapeutic intervention.
A molecular classification of papillary renal cell carcinoma.
TLDR
Two molecular subclasses of PRCC are reported, which are biologically and clinically distinct and may be readily distinguished in a clinical setting and identified two highly distinct molecular PRCC subclasses with morphologic correlation.
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection
TLDR
Genomic data from 65 kidney-derived cell lines are compared to three renal cancer subtypes to stratify mutations and copy number alterations for important kidney cancer genes by the consistency between databases, and classify cell lines into established gene expression-based indolent and aggressive subtypes.
Targeted Therapy for Metastatic Renal Cell Carcinoma.
TLDR
The current evidence did not show the best treatment sequencing after first-line TKI failure, and several new drugs are still being investigated and waiting for the result of phase II or III clinical trial, and this might change the standard therapy for mRCC in the future.
The PI3K/AKT Pathway and Renal Cell Carcinoma.
Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma
TLDR
This in situ study militates against the intuitive dogma where high expression of drug efflux transporters indicates poor survival, but demonstrates that expression of single drugtransporters might indicate even improved survival.
...
1
2
3
4
5
...